{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T18:06:45Z","timestamp":1778350005800,"version":"3.51.4"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,11,17]],"date-time":"2008-11-17T00:00:00Z","timestamp":1226880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2009,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is growing evidence that the ergot\u2010derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot\u2010derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot\u2010derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot\u2010derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot\u2010derived dopamine agonists may not be limited to heart valves. For nonergot\u2010derived dopamine agonists, no drug safety signals were evident. \u00a9 2008 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.22385","type":"journal-article","created":{"date-parts":[[2008,11,17]],"date-time":"2008-11-17T17:06:22Z","timestamp":1226941582000},"page":"129-133","source":"Crossref","is-referenced-by-count":64,"title":["Cardiac and noncardiac fibrotic reactions caused by ergot\u2010and nonergot\u2010derived dopamine agonists"],"prefix":"10.1002","volume":"24","author":[{"given":"Frank","family":"Andersohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edeltraut","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200511033531822"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000083985.00343.F2"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062222"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70218-1"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20200"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2004.09.014"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09051013"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2000.101004283.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20330"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21225"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200305000-00001"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100258"},{"key":"e_1_2_6_14_2","unstructured":"US Food and Drug Administration. Adverse Event Reporting System (AERS). Available at:http:\/\/www.fda.gov\/cder\/aers\/default.htm. Accessed on July 31 2008."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90150-1"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410300416"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200209000-00013"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068265"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730060-00009"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22385","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22385","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.22385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:21:28Z","timestamp":1760959288000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.22385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,15]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,15]]}},"alternative-id":["10.1002\/mds.22385"],"URL":"https:\/\/doi.org\/10.1002\/mds.22385","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,15]]}}}